Standage B A, Schuman E S, Ackerman D, Gross G F, Ragsdale J W
Department of Surgery, Good Samaritan Hospital and Medical Center, Portland, OR.
Am J Surg. 1993 May;165(5):650-4. doi: 10.1016/s0002-9610(05)80454-4.
Erythropoietin (EPO) is highly efficacious in the treatment of the anemia of chronic renal failure. Evidence for a reported serious side effect, increased dialysis graft thrombosis, is equivocal. Sixty-four hemodialysis patients utilizing polytetrafluoroethylene (PTFE) grafts were treated with EPO. The patients served as their own historical controls. There were 1.188 thrombectomies and 0.222 mechanical problems per 1,000 patient-days prior to the initiation of EPO treatment. With EPO, the values were 0.656 and 0.222, respectively. Patients were separated into low-, medium-, and high-dose EPO groups and analyzed within groups for the effect of EPO and between groups for a dose-dependent response. According to an analysis of variance procedure, there was no statistically significant differences between the groups, which suggests that EPO is not thrombogenic to dialysis grafts.
促红细胞生成素（EPO）在治疗慢性肾衰竭贫血方面疗效显著。关于其一种已报道的严重副作用——透析移植血管血栓形成增加——的证据并不明确。64名使用聚四氟乙烯（PTFE）移植血管的血液透析患者接受了EPO治疗。这些患者以自身作为历史对照。在开始EPO治疗前，每1000患者日有1.188次血栓切除术和0.222次机械问题。使用EPO后，相应数值分别为0.656和0.222。患者被分为低剂量、中剂量和高剂量EPO组，并在组内分析EPO的效果，在组间分析剂量依赖性反应。根据方差分析程序，各组之间没有统计学上的显著差异，这表明EPO对透析移植血管没有致血栓作用。
